Renske ten Ham

Renske ten Ham is an assistant professor at the UMC Utrecht in the Netherlands and specializes in health economics & health technology assessment (HTA) of regenerative medicines, including gene and cell-based therapies. Trained as a pharmacist and with an MSc in HTA, she holds a PhD in Drug Innovation titled: “Development, market authorization and market access of gene- and cell-based therapies”.

Over the years Renske conducted research at the University of California, San Francisco (UCSF), spend time at the Dutch Medicines Evaluation Board (CBG-MEB), Dutch National Health Care Institute (Zorginstituut Nederland) and collaborated with several research groups, amongst which the Center of Health Economics at the University of York. 

At the Julius Center Renske is lead of the Regenerative Medicines (RM) team within the Health Economic Evaluation-group. She strives to increase translation of RM and (academic) gene and cell-based therapies towards implementation in healthcare services. In doing so her research focusses on payment models, development cost, (early) economic evaluations and funding/business models. She aims to contribute to better understanding of the fit between innovative therapies and existing development frameworks. This is not only relevant for RM but also for future biomedical innovations.